The Skill to Heal. The Heart to Care.

Phone: 505.842.8171

dotAfter Hours: 505.857.3877

dotPharmacy: 505.822.3911




Latest Cancer News

Investigational Drug Pembrolizumab Shows Anticancer Activity in Advanced Melanoma (07-30-2014)

Recent findings reported in The Lancet indicate that the investigational drug pembrolizumab may be effective in patients with advanced melanoma that has progressed after treatment with Yervoy® (ipilimumab).[1] These findings build on previous research... Continue Reading

Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Information (07-30-2014)

Jakafi is a prescription medicine approved by the U.S. Food and Drug Administration to treat people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF.  It was... Continue Reading

Studies Evaluate Robot Assisted Cystectomy Treatment of Bladder Cancer (07-29-2014)

The bladder is a hollow organ located in the pelvis. Its primary function is to store urine. The bladder has a muscular wall that allows it to get larger and smaller as urine is stored or emptied. Bladder cancer is diagnosed in roughly 50,000 men and... Continue Reading

New Research Questions Early Prostate Cancer Treatment Options (07-28-2014)

Researchers at The University of Texas MD Anderson Cancer Center recently published their latest findings on the role a diagnosing urologist plays in deciding whether older men with low-risk prostate cancer should receive treatment for their disease,... Continue Reading

Study of Combination Therapy in Cutaneous Melanoma Stopped Early to Allow Crossover (07-25-2014)

An Independent Data Monitoring Committee recently recommended that a clinical study of the combination treatment Mekinist™ (trametinib) plus Tafinlar™ (dabrafenib) versus Zelboraf® (vemurafenib) for metastatic cutaneous melanoma patients be stopped... Continue Reading

FDA Approves Beleodaq for Peripheral T-cell Lymphoma (07-24-2014)

The FDA announces its approval of Beleodaq (belinostat), a histone deacetylase inhibitor for treating peripheral T-cell lymphoma (PTCL), based on the results of the BELIEF study that found an overall response rate of nearly 26% among treated patients. PTCL... Continue Reading

HPV Testing Found to Be More Effective Than Pap Smears in Evaluating Cervical Cancer Risk (07-23-2014)

Researchers at the National Cancer Institute reported that testing for HPV (human papillomavirus) is the most effective way to determine whether a woman is at risk for developing cervical cancer in the near future. Specifically, the study found that negative... Continue Reading

Revlimid, Velcade, and Dexamethasone Followed by Revlimid Maintenance Appears Promising (07-22-2014)

Researchers from France recently published the preliminary results of a clinical trial evaluating chemotherapy induction and consolidation treatment with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (RVD) followed by Revlimid maintenance... Continue Reading

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment (07-21-2014)

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood... Continue Reading

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival (07-10-2014)

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic cancer that had progressed on Gemzar® (gemcitabine).... Continue Reading

TAS-102 Improves Survival in Advanced Colorectal Cancer (07-9-2014)

Researchers recently reported that the new combination agent TAS-102 improves overall survival in patients whose metastatic colorectal cancer is refractory to standard therapies. These results were recently reported at the ESMO 16th World Congress on... Continue Reading

Trial Evaluating Nivolumab in Advanced Melanoma Halted Early Because of Superior Results (07-8-2014)

Bristol-Myers Squibb announced on Tuesday that its clinical trial evaluating cancer immunotherapy nivolumab, which is being developed in advanced melanoma was halted early after it was determined that the drug was likely to prolong survival. Nivolumab... Continue Reading

Next Page »